<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="brief-report"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Psychopharmacol Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Clin Psychopharmacol Neurosci</journal-id><journal-title-group><journal-title>Clinical Psychopharmacology and Neuroscience</journal-title></journal-title-group><issn pub-type="ppub">1738-1088</issn><issn pub-type="epub">2093-4327</issn><publisher><publisher-name>Korean College of Neuropsychopharmacology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">9329102</article-id><article-id pub-id-type="pmid">35879042</article-id><article-id pub-id-type="doi">10.9758/cpn.2022.20.3.573</article-id><article-id pub-id-type="publisher-id">cpn-20-3-573</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>The Cumulative Effect of Antipsychotic Usage on Mortality in Schizophrenia: A Nationwide Population-based Cohort Study in Korea</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4486-695X</contrib-id><name><surname>Kim</surname><given-names>Gyurin</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4938-4116</contrib-id><name><surname>Rim</surname><given-names>Soo Jung</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4208-0024</contrib-id><name><surname>Jo</surname><given-names>Minkyung</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2916-7421</contrib-id><name><surname>Lee</surname><given-names>Min Geu</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5561-2141</contrib-id><name><surname>Park</surname><given-names>Se Jin</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4623-9899</contrib-id><name><surname>Park</surname><given-names>Subin</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Research Planning, Seoul, <country>Korea</country></aff><aff id="aff2"><label>2</label>Mental Health Research Institute, National Center for Mental Health, Seoul, <country>Korea</country></aff><author-notes><corresp id="cor1">
<bold>Address for correspondence:</bold> Subin Park Mental Health Research Institute, National Center for Mental Health, 127 Yongmasan-ro, Gwangjin-gu, Seoul 04933, Korea, E-mail: <email xlink:href="subin-21@hanmail.net">subin-21@hanmail.net</email>, ORCID: <ext-link xlink:href="https://orcid.org/0000-0002-4623-9899" ext-link-type="uri">https://orcid.org/0000-0002-4623-9899</ext-link>
</corresp></author-notes><pub-date pub-type="ppub"><day>31</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>8</month><year>2022</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>20</volume><issue>3</issue><fpage>573</fpage><lpage>577</lpage><history><date date-type="received"><day>16</day><month>12</month><year>2021</year></date><date date-type="rev-recd"><day>21</day><month>3</month><year>2022</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2022</year></date></history><permissions><copyright-statement>Copyright&#x000a9; 2022, Korean College of Neuropsychopharmacology</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec sec-type="objective"><title>Objective</title><p>To investigate the cumulative effect of antipsychotics at different dosages on mortality in patients with schizo-phrenia.</p></sec><sec sec-type="methods"><title>Methods</title><p>We analyzed data from the Korean National Health Insurance System&#x02212;National Sample Cohort covering the 2002&#x02212;2013 period. We used Cox regression analysis to calculate hazard ratios for mortality risks according to cumulative antipsychotic exposure levels (low, moderate, and high).</p></sec><sec sec-type="results"><title>Results</title><p>Our analyses revealed no significant association between antipsychotic exposure and mortality (either all-cause or cause-specific) in patients with schizophrenia.</p></sec><sec sec-type="conclusion"><title>Conclusion</title><p>Our results imply that the excess mortality of patients with schizophrenia is attributable to factors other than antipsychotic usage.</p></sec></abstract><kwd-group><kwd>Schizophrenia</kwd><kwd>Antipsychotics</kwd><kwd>Mortality</kwd><kwd>South Korea.</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Schizophrenia is a mental disorder that features symptoms such as delusions, hallucinations, and disorganized speech and behavior, and it causes multifaceted dysfunction in life [<xref rid="ref1" ref-type="bibr">1</xref>]. The median lifetime prevalence rate of schizophrenia is reported as 0.48% (interquartile range, 0.34&#x02212;0.85%) [<xref rid="ref2" ref-type="bibr">2</xref>]. In spite of the low prevalence rate, the burden that schizophrenia places on patients, family members, and society is tremendous [<xref rid="ref3" ref-type="bibr">3</xref>]. According to the Global Burden of Disease Study 2017, there were 1.13 million incident cases of schizophrenia and 12.66 million (95% uncertainty interval, 9.48&#x02212;15.56 million) disability- adjusted life years due to schizophrenia in 2017 [<xref rid="ref4" ref-type="bibr">4</xref>].</p><p>One of the major burdens of schizophrenia is premature mortality [<xref rid="ref5" ref-type="bibr">5</xref>]. Patients with schizophrenia have a higher risk of all-cause mortality and mortality due to specific causes (e.g., cardiovascular disease, neoplasm, and suicide) when compared with the general population [<xref rid="ref6" ref-type="bibr">6</xref>,<xref rid="ref7" ref-type="bibr">7</xref>]. This premature mortality has generally been attributed to factors such as unhealthy lifestyles, alcohol and substance abuse, and comorbid somatic diseases [<xref rid="ref6" ref-type="bibr">6</xref>,<xref rid="ref8" ref-type="bibr">8</xref>]. Another factor potentially related to mortality in patients with schizophrenia is their antipsychotic usage, but the literature contains mixed results. A systematic review suggested that long-term usage of antipsychotics may increase mortality [<xref rid="ref9" ref-type="bibr">9</xref>], but other studies have found that exposure (any, current, or cumulative) to antipsychotics reduces mortality risks [<xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr"/><xref rid="ref12" ref-type="bibr"/><xref rid="ref13" ref-type="bibr"/><xref rid="ref14" ref-type="bibr"/>-<xref rid="ref15" ref-type="bibr">15</xref>]. Moreover, a recent study from Sweden [<xref rid="ref16" ref-type="bibr">16</xref>] found that exposure to antipsychotics exhibited a U-shaped association with all-cause mortality, with the no-usage group having the highest overall mortality rate followed by the high-exposure group. The authors suggested that adequate antipsychotic dosages (low or moderate) lower mortality risks for patients with schizophrenia and that excess mortality of patients with schizophrenia is due to other factors, not antipsychotic usage [<xref rid="ref16" ref-type="bibr">16</xref>].</p><p>However, studies on the effect of antipsychotics on mortality in patients with schizophrenia are scarce, and studies on the cumulative dose-specific effects of antipsychotics on mortality are rare. It is thus difficult to draw firm conclusions on the cumulative dose-specific effects of antipsychotics on mortality. We therefore conducted a nationwide population-based cohort study to investigate the cumulative dose-specific effects of antipsychotics on all-cause and cause-specific mortality in patients with schizophrenia in the Republic of Korea.</p></sec><sec sec-type="other"><title>METHODS</title><p>We conducted this study with data from the Korean National Health Insurance System-National Sample Cohort (NHIS-NSC) provided by the Korean National Health Insurance Corporation. The Korean NHIS system, which was established for claims reimbursement purposes, includes the entire national population (approximately 50 million people). For representative sampling of the NHIS data, 756 strata based on 18 groups for age, 21 groups for income level by insurance type, and two groups for sex were set up with data from 2002. The NHIS-NSC data sample includes 1,025,340 individuals, which is equivalent to 2.2% of all NHIS members in 2002.</p><p>For the present study, we selected individuals from the NHIS-NSC dataset who had at least one primary diagnosis (outpatient or inpatient) for the International Classification of Diseases, 10th Revision (ICD-10) codes of F20 to F25, which correspond to schizophrenia and related diagnoses. In total, 9,978 individuals were included in the present study. We followed these individuals from their initial diagnosis dates until death or December 31, 2013, whichever came first. Whether the patients were still alive on December 31, 2013, was determined by linkage to the database of the Statistics Korea and the specific cause of mortality was recorded based on the ICD-10 codes. The outcomes of interest were all-cause mortality (ICD-10 codes A00 to Z99) and three specific causes of mortality: suicide (ICD-10 codes X60 to X84), cardiovascular disease (ICD-10 codes I00 to I99), and neoplasms (ICD-10 codes C00 to D49).</p><p>Antipsychotic usage levels were determined based on prescription records from the observation period. Pre-scription drugs were classified according to the Anatomical Therapeutic Chemical coding system, under which antipsychotics are coded as N05A; antidepressants are coded as N06AA, N06AB, N06AG, or N06AX; and benzodiazepines are coded as N03AE, N05BA, or N05CD. The antipsychotic drugs investigated in this study included amisulpride, aripiprazole, chlorpromazine, clozapine, haloperidol, levomepromazine, olanzapine, paliperidone, perphenazine, pimozide, quetiapine, risperidone, sulpiride, ziprasidone, and zotepine. The prescribed medication doses were estimated based on defined daily doses (DDDs), and cumulative antipsychotic doses were calculated by multiplying the prescribed medication dose by the number of prescription days and dividing by the DDD. If a participant was prescribed with more than one antipsychotic medication, all antipsychotic medication that the participants were prescribed with was considered when calculating the cumulative DDD. For instance, if a participant has been prescribed with 100 mg of Olanzapine (DDD<sub>Olanzapine</sub> = 10 mg, cumulative DDD<sub>olanzapine</sub> = 100 mg/10 mg = 10DDD) and 6,000 mg of Clozapine (DDD<sub>clozapine</sub> = 300 mg, cumulative DDD<sub>clozapine</sub> = 6,000 mg/300 mg = 20DDD) during the follow up period, this participants&#x02019; cumulative DDD (cDDD) would be 30 DDD. The selected individuals were categorized into four cDDD groups: 1) non-use, defined as no antipsychotic usage during the observation period; 2) low-dose, defined as having a nonzero daily cDDD under 0.5; 3) moderate- dose, defined as having a daily cDDD of 0.5 to 1.5; and 4) high-dose, defined as having a daily cDDD greater than 1.5. This categorization scheme was used in a previous study [<xref rid="ref15" ref-type="bibr">15</xref>].</p><p>The selected individuals were also categorized into 5-year age groups (age of diagnosis), and the Charlson Comorbidity Index (CCI) [<xref rid="ref17" ref-type="bibr">17</xref>] was calculated for each individual. Under the CCI system, certain physical diseases (e.g., diabetes, tumor, etc.) have their own weight based on their severity. A score of 0 indicates that an individual does not have a comorbid disease, and higher CCI scores indicate that the patient has multiple comorbid diseases or a severe disease.</p><p>This study was approved by the Institutional Review Board of the National Center for Mental Health (116271-2021-09).</p><sec><title>Statistical Analysis</title><p>To quantify the associations between antipsychotic cDDD groups and mortality rates, we used Cox regression analysis to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). The no-use condition consistently served as the reference group in HR calculations. Our Cox regression analysis included adjustments for sex, age, use of other medications (antidepressants and benzodiazepines), and CCI scores [<xref rid="ref15" ref-type="bibr">15</xref>]. All analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC, USA), and <italic toggle="yes">p</italic>values less than or equal to 0.05 were considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The descriptive characteristics of the included indivi-duals are presented in <xref rid="T1" ref-type="table">Table 1</xref>. The adjusted hazard ratios for all-cause and cause-specific mortality according to different antipsychotic exposure levels are listed in <xref rid="T2" ref-type="table">Table 2</xref>.</p><p>Before controlling for sex, age, use of other medications, and CCI scores, high-dose antipsychotic usage was associated with a reduced risk of all-cause mortality (crude HR [CHR] = 0.56, 95% CI = 0.42&#x02212;0.75) and mortality due to cardio-vascular disease (CHR = 0.35, 95% CI = 0.16&#x02212;0.74), and moderate-dose usage was associated with a lower risk of all-cause mortality (CHR = 0.71, 95% CI = 0.55&#x02212;0.91). However, these associations disappeared after controlling for the covariates.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this population-based cohort study, we investigated the effect of cumulative antipsychotic usage on all-cause and cause-specific mortality in patients with schizophrenia. After controlling for covariates, there was no significant association between antipsychotic usage at any dosage level and all-cause or cause-specific mortality in patients with schizophrenia.</p><p>Previous studies suggest that the use of clozapine [<xref rid="ref18" ref-type="bibr">18</xref>,<xref rid="ref19" ref-type="bibr">19</xref>] or long-acting injection antipsychotic drugs [<xref rid="ref20" ref-type="bibr">20</xref>,<xref rid="ref21" ref-type="bibr">21</xref>] lowers the mortality of those with schizophrenia. However, to date, only a few studies have examined the effect of cumulative antipsychotic usage on mortality in patients with schizophrenia and more research needs to be done to achieve consensus on the cumulative effect of antipsychotic use in schizophrenia mortality. These studies generally reported that antipsychotic usage lowered mortality risks in patients with schizophrenia, although dose-specific effects varied between studies. Two studies from Sweden [<xref rid="ref15" ref-type="bibr">15</xref>] and Finland [<xref rid="ref18" ref-type="bibr">18</xref>] found that moderate and high doses of antipsychotics were associated with reduced overall mortality for patients with schizophrenia. Another study from Sweden [<xref rid="ref16" ref-type="bibr">16</xref>] found that low and moderate antipsychotic doses were associated with reduced mortality risks for patients with schizophrenia. Taipale <italic toggle="yes">et al</italic>. [<xref rid="ref18" ref-type="bibr">18</xref>] suggested that antipsychotic usage reduces mortality by alleviating the symptoms of schizophrenia. Moreover, antipsychotic usage lowers cardiovascular mortality by reducing unhealthy behaviors (e.g., smoking and alcohol abuse) and stress [<xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr"/>-<xref rid="ref24" ref-type="bibr">24</xref>]. Our findings also imply that excess mortality in schizophrenia may be attributable to factors other than antipsychotic treatment, which is in line with a previous study&#x02019;s findings [<xref rid="ref16" ref-type="bibr">16</xref>]. It is generally believed that excess mortality in patients with schizophrenia is largely attributable to unhealthy lifestyle factors, such as smoking, alcohol abuse, poor diet, and lack of exercise [<xref rid="ref25" ref-type="bibr">25</xref>]. However, the factors associated with mortality in patients with schizophrenia remain unclear. Future studies are needed to identify these various factors.</p><p>This study had several limitations. First, we conducted a retrospective cohort study utilizing a national registry data. Therefore, there were limited information that was retrievable (e.g., the severity of schizophrenia could not be measured), and the presence or absence of each disease was classified based solely on ICD-10 codes. Second, because we only had access to data concerning physician- issued prescriptions, we could not determine the degree of adherence to antipsychotic therapy. Last but not least, the NHIS-NSC is comprised of 2% of the entire popula-tion in Korea and schizophrenia is a mental disorder with a relatively low prevalence rate. Therefore, future studies need to be conducted while utilizing the entire population in Korea to confirm the results found in this study. The main strength of our study is that it used a nationally representative sample.</p><p>In conclusion, our results indicate that there is no significant association between antipsychotic usage at any dosage level and all-cause or cause-specific mortality in patients with schizophrenia. This implies that the excess mortality of patients with schizophrenia is attributable to factors other than antipsychotic use.</p></sec></body><back><fn-group><fn><p>
<bold>Funding</bold>
</p><p>This work was supported by a clinical research grant (no. 2021-03) from the National Center for Mental Health, Republic of Korea.</p></fn><fn fn-type="COI-statement"><p>
<bold>Conflicts of Interest</bold>
</p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn><p>
<bold>Author Contributions</bold>
</p><p>Conceptualization: Subin Park, Gyurin Kim. Methodology: Minkyung Jo. Statistical analysis: Min Geu Lee. Reference review: Gyurin Kim, Soo Jung Rim, Se Jin Park. Writing&#x02212;original draft: Gyurin Kim, Soo Jung Rim, Se Jin Park, Min Geu Lee. Writing&#x02212;review and editing: Subin Park, Se Jin Park, Soo Jung Rim. Approval of final manuscript: all authors.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="book"><collab collab-type="author">American Psychiatric Association</collab><year>2013</year><source>Diagnostic and statistical manual of mental disorders: DSM-5</source><publisher-name>American Psychiatric Association</publisher-name><publisher-loc>Arlington</publisher-loc><pub-id pub-id-type="doi">10.1176/appi.books.9780890425596</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simeone</surname><given-names>JC</given-names></name>
<name><surname>Ward</surname><given-names>AJ</given-names></name>
<name><surname>Rotella</surname><given-names>P</given-names></name>
<name><surname>Collins</surname><given-names>J</given-names></name>
<name><surname>Windisch</surname><given-names>R</given-names></name>
</person-group><year>2015</year><article-title>An evaluation of variation in published estimates of schizophrenia prevalence from 1990&#x02212;2013: a systematic literature review</article-title><source>BMC Psychiatry</source><volume>15</volume><fpage>193</fpage><pub-id pub-id-type="doi">10.1186/s12888-015-0578-7</pub-id><!--<pub-id pub-id-type="pmcid">PMC4533792</pub-id>--><?supplied-pmid 26263900?><pub-id pub-id-type="pmid">26263900</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chong</surname><given-names>HY</given-names></name>
<name><surname>Teoh</surname><given-names>SL</given-names></name>
<name><surname>Wu</surname><given-names>DB</given-names></name>
<name><surname>Kotirum</surname><given-names>S</given-names></name>
<name><surname>Chiou</surname><given-names>CF</given-names></name>
<name><surname>Chaiyakunapruk</surname><given-names>N</given-names></name>
</person-group><year>2016</year><article-title>Global economic burden of schizophrenia: a systematic review</article-title><source>Neuropsychiatr Dis Treat</source><volume>12</volume><fpage>357</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.2147/NDT.S96649</pub-id><!--<pub-id pub-id-type="pmcid">PMC4762470</pub-id>--><?supplied-pmid 26937191?><pub-id pub-id-type="pmid">26937191</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>H</given-names></name>
<name><surname>Liu</surname><given-names>Q</given-names></name>
<name><surname>Li</surname><given-names>N</given-names></name>
<name><surname>Guo</surname><given-names>L</given-names></name>
<name><surname>Gao</surname><given-names>F</given-names></name>
<name><surname>Bai</surname><given-names>L</given-names></name>
<etal/>
</person-group><year>2017</year><article-title>Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017</article-title><source>Epidemiol Psychiatr Sci</source><volume>29</volume><elocation-id>e91</elocation-id><pub-id pub-id-type="doi">10.1017/S2045796019000891</pub-id><!--<pub-id pub-id-type="pmcid">PMC7214712</pub-id>--><?supplied-pmid 31928566?><pub-id pub-id-type="pmid">31928566</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Hert</surname><given-names>M</given-names></name>
<name><surname>Dekker</surname><given-names>JM</given-names></name>
<name><surname>Wood</surname><given-names>D</given-names></name>
<name><surname>Kahl</surname><given-names>KG</given-names></name>
<name><surname>Holt</surname><given-names>RI</given-names></name>
<name><surname>M&#x000f6;ller</surname><given-names>HJ</given-names></name>
</person-group><year>2009</year><article-title>Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)</article-title><source>Eur Psychiatry</source><volume>24</volume><fpage>412</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1016/j.eurpsy.2009.01.005</pub-id><?supplied-pmid 19682863?><pub-id pub-id-type="pmid">19682863</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olfson</surname><given-names>M</given-names></name>
<name><surname>Gerhard</surname><given-names>T</given-names></name>
<name><surname>Huang</surname><given-names>C</given-names></name>
<name><surname>Crystal</surname><given-names>S</given-names></name>
<name><surname>Stroup</surname><given-names>TS</given-names></name>
</person-group><year>2015</year><article-title>Premature mortality among adults with schizophrenia in the United States</article-title><source>JAMA Psychiatry</source><volume>72</volume><fpage>1172</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.1737</pub-id><?supplied-pmid 26509694?><pub-id pub-id-type="pmid">26509694</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ko</surname><given-names>YS</given-names></name>
<name><surname>Tsai</surname><given-names>HC</given-names></name>
<name><surname>Chi</surname><given-names>MH</given-names></name>
<name><surname>Su</surname><given-names>CC</given-names></name>
<name><surname>Lee</surname><given-names>IH</given-names></name>
<name><surname>Chen</surname><given-names>PS</given-names></name>
<etal/>
</person-group><year>2018</year><article-title>Higher mortality and years of potential life lost of suicide in patients with schizophrenia</article-title><source>Psychiatry Res</source><volume>270</volume><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2018.09.038</pub-id><?supplied-pmid 30342411?><pub-id pub-id-type="pmid">30342411</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Galletly</surname><given-names>CA</given-names></name>
</person-group><year>2017</year><article-title>Premature death in schizophrenia: bridging the gap</article-title><source>Lancet Psychiatry</source><volume>4</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(17)30079-2</pub-id><?supplied-pmid 28237638?><pub-id pub-id-type="pmid">28237638</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weinmann</surname><given-names>S</given-names></name>
<name><surname>Read</surname><given-names>J</given-names></name>
<name><surname>Aderhold</surname><given-names>V</given-names></name>
</person-group><year>2009</year><article-title>Influence of antipsychotics on mortality in schizophrenia: systematic review</article-title><source>Schizophr Res</source><volume>113</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2009.05.018</pub-id><?supplied-pmid 19524406?><pub-id pub-id-type="pmid">19524406</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crump</surname><given-names>C</given-names></name>
<name><surname>Winkleby</surname><given-names>MA</given-names></name>
<name><surname>Sundquist</surname><given-names>K</given-names></name>
<name><surname>Sundquist</surname><given-names>J</given-names></name>
</person-group><year>2013</year><article-title>Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study</article-title><source>Am J Psychiatry</source><volume>170</volume><fpage>324</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2012.12050599</pub-id><?supplied-pmid 23318474?><pub-id pub-id-type="pmid">23318474</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cullen</surname><given-names>BA</given-names></name>
<name><surname>McGinty</surname><given-names>EE</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Dosreis</surname><given-names>SC</given-names></name>
<name><surname>Steinwachs</surname><given-names>DM</given-names></name>
<name><surname>Guallar</surname><given-names>E</given-names></name>
<etal/>
</person-group><year>2013</year><article-title>Guideline-concordant antipsychotic use and mortality in schizophrenia</article-title><source>Schizophr Bull</source><volume>39</volume><fpage>1159</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbs097</pub-id><!--<pub-id pub-id-type="pmcid">PMC3756776</pub-id>--><?supplied-pmid 23112292?><pub-id pub-id-type="pmid">23112292</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baandrup</surname><given-names>L</given-names></name>
<name><surname>Gasse</surname><given-names>C</given-names></name>
<name><surname>Jensen</surname><given-names>VD</given-names></name>
<name><surname>Glenthoj</surname><given-names>BY</given-names></name>
<name><surname>Nordentoft</surname><given-names>M</given-names></name>
<name><surname>Lublin</surname><given-names>H</given-names></name>
<etal/>
</person-group><year>2010</year><article-title>Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study</article-title><source>J Clin Psychiatry</source><volume>71</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.4088/JCP.08m04818yel</pub-id><?supplied-pmid 19895781?><pub-id pub-id-type="pmid">19895781</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiihonen</surname><given-names>J</given-names></name>
<name><surname>Haukka</surname><given-names>J</given-names></name>
<name><surname>Taylor</surname><given-names>M</given-names></name>
<name><surname>Haddad</surname><given-names>PM</given-names></name>
<name><surname>Patel</surname><given-names>MX</given-names></name>
<name><surname>Korhonen</surname><given-names>P</given-names></name>
</person-group><year>2011</year><article-title>A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia</article-title><source>Am J Psychiatry</source><volume>168</volume><fpage>603</fpage><lpage>609</lpage><comment>Erratum in: Am J Psychiatry 2012;169:223</comment><pub-id pub-id-type="doi">10.1176/appi.ajp.2011.10081224</pub-id><?supplied-pmid 21362741?><pub-id pub-id-type="pmid">21362741</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiihonen</surname><given-names>J</given-names></name>
<name><surname>L&#x000f6;nnqvist</surname><given-names>J</given-names></name>
<name><surname>Wahlbeck</surname><given-names>K</given-names></name>
<name><surname>Klaukka</surname><given-names>T</given-names></name>
<name><surname>Niskanen</surname><given-names>L</given-names></name>
<name><surname>Tanskanen</surname><given-names>A</given-names></name>
<etal/>
</person-group><year>2009</year><article-title>11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)</article-title><source>Lancet</source><volume>374</volume><fpage>620</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60742-X</pub-id><?supplied-pmid 19595447?><pub-id pub-id-type="pmid">19595447</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tiihonen</surname><given-names>J</given-names></name>
<name><surname>Mittendorfer-Rutz</surname><given-names>E</given-names></name>
<name><surname>Torniainen</surname><given-names>M</given-names></name>
<name><surname>Alexanderson</surname><given-names>K</given-names></name>
<name><surname>Tanskanen</surname><given-names>A</given-names></name>
</person-group><year>2016</year><article-title>Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study</article-title><source>Am J Psychiatry</source><volume>173</volume><fpage>600</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2015.15050618</pub-id><?supplied-pmid 26651392?><pub-id pub-id-type="pmid">26651392</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torniainen</surname><given-names>M</given-names></name>
<name><surname>Mittendorfer-Rutz</surname><given-names>E</given-names></name>
<name><surname>Tanskanen</surname><given-names>A</given-names></name>
<name><surname>Bj&#x000f6;rkenstam</surname><given-names>C</given-names></name>
<name><surname>Suvisaari</surname><given-names>J</given-names></name>
<name><surname>Alexanderson</surname><given-names>K</given-names></name>
<etal/>
</person-group><year>2015</year><article-title>Antipsychotic treatment and mortality in schizophrenia</article-title><source>Schizophr Bull</source><volume>41</volume><fpage>656</fpage><lpage>663</lpage><comment>Erratum in: Schizophr Bull 2016;42:528</comment><pub-id pub-id-type="doi">10.1093/schbul/sbu164</pub-id><!--<pub-id pub-id-type="pmcid">PMC4393693</pub-id>--><?supplied-pmid 25422511?><pub-id pub-id-type="pmid">25422511</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sundararajan</surname><given-names>V</given-names></name>
<name><surname>Henderson</surname><given-names>T</given-names></name>
<name><surname>Perry</surname><given-names>C</given-names></name>
<name><surname>Muggivan</surname><given-names>A</given-names></name>
<name><surname>Quan</surname><given-names>H</given-names></name>
<name><surname>Ghali</surname><given-names>WA</given-names></name>
</person-group><year>2004</year><article-title>New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality</article-title><source>J Clin Epidemiol</source><volume>57</volume><fpage>1288</fpage><lpage>1294</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2004.03.012</pub-id><?supplied-pmid 15617955?><pub-id pub-id-type="pmid">15617955</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taipale</surname><given-names>H</given-names></name>
<name><surname>Tanskanen</surname><given-names>A</given-names></name>
<name><surname>Meht&#x000e4;l&#x000e4;</surname><given-names>J</given-names></name>
<name><surname>Vattulainen</surname><given-names>P</given-names></name>
<name><surname>Correll</surname><given-names>CU</given-names></name>
<name><surname>Tiihonen</surname><given-names>J</given-names></name>
</person-group><year>2020</year><article-title>20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)</article-title><source>World Psychiatry</source><volume>19</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1002/wps.20699</pub-id><!--<pub-id pub-id-type="pmcid">PMC6953552</pub-id>--><?supplied-pmid 31922669?><pub-id pub-id-type="pmid">31922669</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vermeulen</surname><given-names>JM</given-names></name>
<name><surname>van Rooijen</surname><given-names>G</given-names></name>
<name><surname>van de Kerkhof</surname><given-names>MPJ</given-names></name>
<name><surname>Sutterland</surname><given-names>AL</given-names></name>
<name><surname>Correll</surname><given-names>CU</given-names></name>
<name><surname>de Haan</surname><given-names>L</given-names></name>
</person-group><year>2019</year><article-title>Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years</article-title><source>Schizophr Bull</source><volume>45</volume><fpage>315</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1093/schbul/sby052</pub-id><!--<pub-id pub-id-type="pmcid">PMC6403051</pub-id>--><?supplied-pmid 29697804?><pub-id pub-id-type="pmid">29697804</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taipale</surname><given-names>H</given-names></name>
<name><surname>Mittendorfer-Rutz</surname><given-names>E</given-names></name>
<name><surname>Alexanderson</surname><given-names>K</given-names></name>
<name><surname>Majak</surname><given-names>M</given-names></name>
<name><surname>Meht&#x000e4;l&#x000e4;</surname><given-names>J</given-names></name>
<name><surname>Hoti</surname><given-names>F</given-names></name>
<etal/>
</person-group><year>2018</year><article-title>Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia</article-title><source>Schizophr Res</source><volume>197</volume><fpage>274</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2017.12.010</pub-id><?supplied-pmid 29274734?><pub-id pub-id-type="pmid">29274734</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>CY</given-names></name>
<name><surname>Fang</surname><given-names>SC</given-names></name>
<name><surname>Shao</surname><given-names>YJ</given-names></name>
</person-group><year>2021</year><article-title>Comparison of long-acting injectable antipsychotics with oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia</article-title><source>JAMA Netw Open</source><volume>4</volume><elocation-id>e218810</elocation-id><comment>Erratum in: JAMA Netw Open 2022;5:e2210829</comment><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.8810</pub-id><!--<pub-id pub-id-type="pmcid">PMC8114136</pub-id>--><?supplied-pmid 33974056?><pub-id pub-id-type="pmid">33974056</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lahti</surname><given-names>M</given-names></name>
<name><surname>Tiihonen</surname><given-names>J</given-names></name>
<name><surname>Wildgust</surname><given-names>H</given-names></name>
<name><surname>Beary</surname><given-names>M</given-names></name>
<name><surname>Hodgson</surname><given-names>R</given-names></name>
<name><surname>Kajantie</surname><given-names>E</given-names></name>
<etal/>
</person-group><year>2012</year><article-title>Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia</article-title><source>Psychol Med</source><volume>42</volume><fpage>2275</fpage><lpage>2285</lpage><pub-id pub-id-type="doi">10.1017/S0033291712000396</pub-id><?supplied-pmid 22405504?><pub-id pub-id-type="pmid">22405504</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laursen</surname><given-names>TM</given-names></name>
<name><surname>Nordentoft</surname><given-names>M</given-names></name>
<name><surname>Mortensen</surname><given-names>PB</given-names></name>
</person-group><year>2014</year><article-title>Excess early mortality in schizophrenia</article-title><source>Annu Rev Clin Psychol</source><volume>10</volume><fpage>425</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1146/annurev-clinpsy-032813-153657</pub-id><?supplied-pmid 24313570?><pub-id pub-id-type="pmid">24313570</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oh</surname><given-names>J</given-names></name>
<name><surname>Nam</surname><given-names>H</given-names></name>
<name><surname>Park</surname><given-names>S</given-names></name>
<name><surname>Chae</surname><given-names>JH</given-names></name>
<name><surname>Kim</surname><given-names>TS</given-names></name>
</person-group><year>2021</year><article-title>Decreased cardio-vascular death in schizophrenia patients treated with antipsychotics: a Korean national cohort study</article-title><source>Schizophr Res</source><volume>228</volume><fpage>417</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2021.01.006</pub-id><?supplied-pmid 33556675?><pub-id pub-id-type="pmid">33556675</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>S</given-names></name>
<name><surname>Inskip</surname><given-names>H</given-names></name>
<name><surname>Barraclough</surname><given-names>B</given-names></name>
</person-group><year>2000</year><article-title>Causes of the excess mortality of schizophrenia</article-title><source>Br J Psychiatry</source><volume>177</volume><fpage>212</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1192/bjp.177.3.212</pub-id><?supplied-pmid 11040880?><pub-id pub-id-type="pmid">11040880</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of the patient sample</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">Characteristics</th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">Number (%)</th></tr></thead><tbody><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Age (yr)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">0&#x02212;19</td><td valign="top" align="center" rowspan="1" colspan="1">432 (5.60)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">20&#x02212;29</td><td valign="top" align="center" rowspan="1" colspan="1">1,313 (17.03)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">30&#x02212;39</td><td valign="top" align="center" rowspan="1" colspan="1">1,711 (22.19)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">40&#x02212;49</td><td valign="top" align="center" rowspan="1" colspan="1">1,806 (23.42)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">50&#x02212;59</td><td valign="top" align="center" rowspan="1" colspan="1">1,080 (14.00)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">60&#x02212;69</td><td valign="top" align="center" rowspan="1" colspan="1">699 (9.06)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">&#x02265; 70</td><td valign="top" align="center" rowspan="1" colspan="1">671 (8.70)</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Sex</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">3,807 (49.36)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">3,905 (50.64)</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Charlson Comorbidity Index</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">2,057 (26.67)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">2,050 (26.58)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1,435 (18.61)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">&#x02265; 3</td><td valign="top" align="center" rowspan="1" colspan="1">2,170 (28.14)</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Antipsychotic exposure</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">No use</td><td valign="top" align="center" rowspan="1" colspan="1">657 (8.52)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">Low use</td><td valign="top" align="center" rowspan="1" colspan="1">2,316 (30.03)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">Moderate use</td><td valign="top" align="center" rowspan="1" colspan="1">3,201 (41.51)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">High use</td><td valign="top" align="center" rowspan="1" colspan="1">1,538 (19.94)</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Cause of mortality</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">All-cause</td><td valign="top" align="center" rowspan="1" colspan="1">842 (10.92)</td></tr><tr><td valign="top" align="left" style="padding-left:20px; text-indent:-10px;" rowspan="1" colspan="1">Cause-specific</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" style="padding-left:25px; text-indent:-10px;" rowspan="1" colspan="1">Cardiovascular disease</td><td valign="top" align="center" rowspan="1" colspan="1">162 (19.24)</td></tr><tr><td valign="top" align="left" style="padding-left:25px; text-indent:-10px;" rowspan="1" colspan="1">Suicide</td><td valign="top" align="center" rowspan="1" colspan="1">166 (19.71)</td></tr><tr><td valign="top" align="left" style="padding-left:25px; text-indent:-10px;" rowspan="1" colspan="1">Neoplasms</td><td valign="top" align="center" rowspan="1" colspan="1">105 (12.47)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Causes of mortality and association with cumulative antipsychotic doses</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" colspan="1">Cause of mortality</th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">No use (n = 657)</th><th rowspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" colspan="1"/><th colspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1">Low dose (n = 2,316)</th><th rowspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" colspan="1"/><th colspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1">Moderate dose (n = 3,201)</th><th rowspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" colspan="1"/><th colspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1">High dose (n = 1,538)</th><th rowspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" colspan="1"/><th colspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1">Use (combined) (n = 7,055)</th></tr><tr><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">
<hr/>
</th><th colspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1">
<hr/>
</th><th colspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1">
<hr/>
</th><th colspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1">
<hr/>
</th><th colspan="3" valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1">
<hr/>
</th></tr><tr><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">Deaths (n)</th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">Deaths (n)</th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">Crude HR (95% CI)</th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">aHR (95% CI)</th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">Deaths (n) </th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">Crude HR (95% CI)</th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">aHR (95% CI)</th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">Deaths (n) </th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">Crude HR (95% CI)</th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">aHR (95% CI)</th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">Deaths (n) </th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">Crude HR (95% CI)</th><th valign="middle" align="center" style="background-color:#d6d6d6;" rowspan="1" colspan="1">aHR (95% CI)</th></tr></thead><tbody><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">All-cause</td><td valign="top" align="center" rowspan="1" colspan="1">76</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">345</td><td valign="top" align="center" rowspan="1" colspan="1">1.23<break/>
(0.96&#x02212;1.57)</td><td valign="top" align="center" rowspan="1" colspan="1">1.05<break/>
(0.82&#x02212;1.35)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">306</td><td valign="top" align="center" rowspan="1" colspan="1">0.71<break/>
(0.55&#x02212;0.91)</td><td valign="top" align="center" rowspan="1" colspan="1">1.14<break/>
(0.88&#x02212;1.47)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">115</td><td valign="top" align="center" rowspan="1" colspan="1">0.56<break/>
(0.42&#x02212;0.75)</td><td valign="top" align="center" rowspan="1" colspan="1">1.22<break/>
(0.91&#x02212;1.65)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">766</td><td valign="top" align="center" rowspan="1" colspan="1">0.84<break/>
(0.66&#x02212;1.06)</td><td valign="top" align="center" rowspan="1" colspan="1">1.11<break/>
(0.87&#x02212;1.40)</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Cardiovascular disease</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">88</td><td valign="top" align="center" rowspan="1" colspan="1">1.72<break/>
(0.98&#x02212;3.02)</td><td valign="top" align="center" rowspan="1" colspan="1">1.34<break/>
(0.76&#x02212;2.38)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">0.60<break/>
(0.33&#x02212;1.09)</td><td valign="top" align="center" rowspan="1" colspan="1">1.23<break/>
(0.67&#x02212;2.24)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">13</td><td valign="top" align="center" rowspan="1" colspan="1">0.35<break/>
(0.16&#x02212;0.74)</td><td valign="top" align="center" rowspan="1" colspan="1">1.26<break/>
(0.58&#x02212;2.75)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">148</td><td valign="top" align="center" rowspan="1" colspan="1">0.89<break/>
(0.51&#x02212;1.54)</td><td valign="top" align="center" rowspan="1" colspan="1">1.30<break/>
(0.75&#x02212;2.25)</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Suicide</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">38</td><td valign="top" align="center" rowspan="1" colspan="1">0.86<break/>
(0.45&#x02212;1.65)</td><td valign="top" align="center" rowspan="1" colspan="1">0.90<break/>
(0.46&#x02212;1.73)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">76</td><td valign="top" align="center" rowspan="1" colspan="1">1.13<break/>
(0.61&#x02212;2.07)</td><td valign="top" align="center" rowspan="1" colspan="1">1.02<break/>
(0.55&#x02212;1.91)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">40</td><td valign="top" align="center" rowspan="1" colspan="1">1.25<break/>
(0.66&#x02212;2.39)</td><td valign="top" align="center" rowspan="1" colspan="1">1.09<break/>
(0.56&#x02212;2.11)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">154</td><td valign="top" align="center" rowspan="1" colspan="1">1.07<break/>
(0.60&#x02212;1.93)</td><td valign="top" align="center" rowspan="1" colspan="1">1.00<break/>
(0.55&#x02212;1.82)</td></tr><tr><td valign="top" align="left" style="padding-left:10px; text-indent:-10px;" rowspan="1" colspan="1">Neoplasms</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">48</td><td valign="top" align="center" rowspan="1" colspan="1">2.12<break/>
(0.91&#x02212;4.94)</td><td valign="top" align="center" rowspan="1" colspan="1">1.54<break/>
(0.66&#x02212;3.61)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">40</td><td valign="top" align="center" rowspan="1" colspan="1">1.13<break/>
(0.48&#x02212;2.66)</td><td valign="top" align="center" rowspan="1" colspan="1">1.93<break/>
(0.81&#x02212;4.57)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">0.66<break/>
(0.24&#x02212;1.78)</td><td valign="top" align="center" rowspan="1" colspan="1">2.07<break/>
(0.75&#x02212;5.71)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">99</td><td valign="top" align="center" rowspan="1" colspan="1">1.32<break/>
(0.58&#x02212;3.02)</td><td valign="top" align="center" rowspan="1" colspan="1">1.72<break/>
(0.76&#x02212;3.93)</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><p>The antipsychotic no-use group was used as a reference group for all HR calculations.</p></fn><fn id="t2fn2"><p>HR, hazard ratio; aHR, HR adjusted for sex, age group, use of medications (i.e., antidepressants, benzodiazepines), and CCI; CCI, Charlson Comorbidity Index; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap></floats-group></article>